Saule Serikova

Exploring new character benchmarks for today’s pharma executives, and whether they have the transformational traits to lead through change.

Outlining the new leadership and C-level roles of tomorrow needed to take on the disruption event on pharma's horizon.

How a strong corporate board can help ignite success in these regions.

Biopharma’s diversity commitment remains a work in progress but the benefits-in measurable ROI-are increasingly clear.